Metabolic therapeutics in angina pectoris: history revisited with perhexiline.
- Publication Type:
- Journal article
- Citation:
- European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology, 2006, 5 (2), pp. 175 - 184
- Issue Date:
- 2006-06
Closed Access
Full metadata record
Field | Value | Language |
---|---|---|
dc.contributor.author | Inglis, S | |
dc.contributor.author | Stewart, S | |
dc.date.accessioned | 2012-02-02T11:13:27Z | |
dc.date.issued | 2006-06 | |
dc.identifier.citation | European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology, 2006, 5 (2), pp. 175 - 184 | |
dc.identifier.issn | 1474-5151 | |
dc.identifier.other | C2 | en_US |
dc.identifier.uri | http://hdl.handle.net/10453/16787 | |
dc.description.abstract | The ever-increasing burden of ischaemic heart disease and its common manifestation chronic angina pectoris calls for the exploration of other treatment options for those patients who despite the maximum conventional pharmacological and surgical interventions continue to suffer. Such exploration has led to the increasing use of new metabolically acting antianginal agents and the re-emergence of an old and somewhat forgotten pharmacological agent, perhexiline maleate. This review aims to update the cardiac nurse with knowledge to manage the care a patient receiving perhexiline maleate treatment and provide a brief review of three new metabolic agents: trimetazidine, ranolazine and etomoxir. | |
dc.format | Print-Electronic | |
dc.language | eng | |
dc.relation.ispartof | European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology | |
dc.relation.ispartof | Verified OK | en_US |
dc.relation.isbasedon | 10.1016/j.ejcnurse.2006.01.001 | |
dc.subject | Humans, Angina Pectoris, Acetanilides, Epoxy Compounds, Piperazines, Trimetazidine, Perhexiline, Carnitine O-Palmitoyltransferase, Fatty Acids, Cardiovascular Agents, Calcium Channel Blockers, Vasodilator Agents, Drug Monitoring, Metabolic Clearance Rate, Treatment Outcome, Nurse's Role, Patient Selection, Half-Life, Nursing Assessment, Patient Education as Topic, Randomized Controlled Trials as Topic, Acetanilides, Angina Pectoris, Calcium Channel Blockers, Cardiovascular Agents, Carnitine O-Palmitoyltransferase, Drug Monitoring, Epoxy Compounds, Fatty Acids, Half-Life, Humans, Metabolic Clearance Rate, Nurse's Role, Nursing Assessment, Patient Education as Topic, Patient Selection, Perhexiline, Piperazines, Randomized Controlled Trials as Topic, Treatment Outcome, Trimetazidine, Vasodilator Agents, Pharmacology, Nursing management, Refractory angina, Perhexiline, Trimetazidine, Ranolazine, Etomoxir, Nursing, 1102 Cardiovascular Medicine And Haematology, 1110 Nursing, 1117 Public Health And Health Services | |
dc.subject | colorectal cancer, biomarkers, blood test, disease risk, stratification | en_US |
dc.subject | Humans; Angina Pectoris; Acetanilides; Epoxy Compounds; Piperazines; Trimetazidine; Perhexiline; Carnitine O-Palmitoyltransferase; Fatty Acids; Cardiovascular Agents; Calcium Channel Blockers; Vasodilator Agents; Drug Monitoring; Metabolic Clearance Rate; Treatment Outcome; Nurse's Role; Patient Selection; Half-Life; Nursing Assessment; Patient Education as Topic; Randomized Controlled Trials as Topic; Acetanilides; Angina Pectoris; Calcium Channel Blockers; Cardiovascular Agents; Carnitine O-Palmitoyltransferase; Drug Monitoring; Epoxy Compounds; Fatty Acids; Half-Life; Humans; Metabolic Clearance Rate; Nurse's Role; Nursing Assessment; Patient Education as Topic; Patient Selection; Perhexiline; Piperazines; Randomized Controlled Trials as Topic; Treatment Outcome; Trimetazidine; Vasodilator Agents; Pharmacology; Nursing management; Refractory angina; Perhexiline; Trimetazidine; Ranolazine, Etomoxir; Nursing | |
dc.subject | Humans | |
dc.subject | Angina Pectoris | |
dc.subject | Acetanilides | |
dc.subject | Epoxy Compounds | |
dc.subject | Piperazines | |
dc.subject | Trimetazidine | |
dc.subject | Perhexiline | |
dc.subject | Carnitine O-Palmitoyltransferase | |
dc.subject | Fatty Acids | |
dc.subject | Cardiovascular Agents | |
dc.subject | Calcium Channel Blockers | |
dc.subject | Vasodilator Agents | |
dc.subject | Drug Monitoring | |
dc.subject | Metabolic Clearance Rate | |
dc.subject | Treatment Outcome | |
dc.subject | Nurse's Role | |
dc.subject | Patient Selection | |
dc.subject | Half-Life | |
dc.subject | Nursing Assessment | |
dc.subject | Patient Education as Topic | |
dc.subject | Randomized Controlled Trials as Topic | |
dc.subject.classification | Oncology and Carcinogenesis | en_US |
dc.title | Metabolic therapeutics in angina pectoris: history revisited with perhexiline. | |
dc.type | Journal article | |
utslib.citation.volume | 2 | |
utslib.citation.volume | 5 | |
utslib.citation.number | 5 | en_US |
utslib.location | Hoboken | en_US |
utslib.citation.startpage | 1177 | en_US |
utslib.citation.endpage | 1186 | en_US |
utslib.identifier.org | DVCRch.Institute for Sustainable Futures | en_US |
utslib.for | 1110 Nursing | |
utslib.for | 1102 Cardiovascular Medicine And Haematology | |
utslib.for | 1117 Public Health And Health Services | |
utslib.percentage | 100 | en_US |
pubs.embargo.period | Not known | |
pubs.organisational-group | /University of Technology Sydney | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Health | |
pubs.organisational-group | /University of Technology Sydney/Strength - Health Services and Practice Research | |
utslib.copyright.status | closed_access | |
pubs.declined | 1970-01-01T00:00:00.0+1000 |
Files in This Item:
Filename | Description | Size | |||
---|---|---|---|---|---|
2010005293OK.pdf | 616.46 kB | Adobe PDF |
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
Abstract:
The ever-increasing burden of ischaemic heart disease and its common manifestation chronic angina pectoris calls for the exploration of other treatment options for those patients who despite the maximum conventional pharmacological and surgical interventions continue to suffer. Such exploration has led to the increasing use of new metabolically acting antianginal agents and the re-emergence of an old and somewhat forgotten pharmacological agent, perhexiline maleate. This review aims to update the cardiac nurse with knowledge to manage the care a patient receiving perhexiline maleate treatment and provide a brief review of three new metabolic agents: trimetazidine, ranolazine and etomoxir.
Please use this identifier to cite or link to this item: